XXXX in users of @entity11796 .

@entity1 @entity12135 @entity308 @entity11796
Prevalence of @entity308 is high among poor, young, Hispanic inner city @entity1 . Depot- @entity11796 ( @entity12135 ) is a popular contraceptive choice in this group. @entity12135 labelling suggests that @entity308 may worsen with use. In order to identify any association of @entity12135 use with worsening @entity308 , we surveyed an English-speaking subset of @entity12135 users in a Title-X funded family planning clinic. Eighty @entity1 completed the CES-D scale on two occasions: once about four weeks after a @entity12135 injection when the subject would have been exposed to the highest blood levels, and once immediately prior to an injection when recent blood levels of the drug would be somewhat lower (or absent preceding the first injection). The median CES-D score was 14. The scores were not related to timing of the test (pre- or post-injection). The @entity308 scores were somewhat higher among those @entity1 receiving their first @entity12135 injection during the study period (i.e., unexposed @entity1 ) and among those @entity1 who had received four or more injections. Scores were unrelated to age or parity, but were somewhat higher in @entity1 who reported fewer years of education or a recent adverse pregnancy outcome. These data provide little evidence of increasing @entity308 with long-term use of @entity12135 and no evidence of a short-term effect of dose (within the contraceptive range) on mood. @entity1 at risk of @entity308 should not be denied @entity12135 as a contraceptive choice.
